IFNΛ3/4 locus polymorphisms and IFNΛ3 circulating levels are associated with COPD severity and outcomes

Egli, Adrian; Mandal, Jyotshna; Schumann, Desiree M.; Roth, Michael; Thomas, Brad; Lorne Tyrrell, D.; Blasi, Francesco; Kostikas, Kostantinos; Boersma, Wim; Milenkovic, Branislava; Lacoma, Alicia; Rentsch, Katharina; Rohde, Gernot G. U.; Louis, Renaud; Aerts, Joachim G.; Welte, Tobias; Torres, Antoni; Tamm, Michael; Stolz, Daiana

doi:10.1186/s12890-018-0616-6

BMC Pulmonary Medicine

Table 2 A comparison of the patient baseline characteristics according to their rs8099917 genotype

From: IFNΛ3/4 locus polymorphisms and IFNΛ3 circulating levels are associated with COPD severity and outcomes

	GG (median, IQR)	TT/TG (median, IQR)	p-value
Gender: Male (n,%)	16 (61.5)	355 (71.9)	0.269
Age, years	70.50 (14.50)	67.00 (13)	0.139
Current smoker (n, %)	4 (15.4)	149 (30.3)	0.125
PY, months	40.00 (36.75)	45.00 (35)	0.261
BMI, kg/m2	27.29 (7.83)	25.86 (6.14)	0.339
Unadjusted Charlson Score	1.00 (2.00)	1.00 (1.00)	0.305
6MWT, m	375 (161.25)	395 (120)	0.362
Exacerbation rate (number of exacerbations/year)	2.00 (3.00)	1.00 (3.00)	0.935
Severe exacerbation rate (number of severe exacerbations/year)	0.58 (0–3)	0.37 (0–8)	0.033
Lung function (post-brd)
FEV₁, in L	1.31 (0.8)	1.32 (0.74)	0.749
FVC, in L	2.53 (1.95)	2.69 (1.07)	0.688
FEV₁/FVC%	49.38 (27.47)	47.00 (22.91)	0.723
FEV₁, % predicted	56.50 (28.17)	49.50 (25.15)	0.314
FVC, % predicted	82.40 (42.75)	80.00 (26.22)	0.349
BODE index			0.659
≤ median of 3	15 (62.5)	302 (67.3)
> median of 3	9 (37.5)	147 (32.7)
Collagen markers [ng/ml]
C3M	25.3 (14.5)	28.6 (11.6)	0.302
C6M	11.0 (9.7)	13.3 (8.1)	0.032
Pro-C3	12.1 (6.1)	10.8 (5.6)	0.684
Pro-C6	8.1 (3.7)	8.0 (0.535)	1.000
GOLD Grade^a (n,%)			0.699
GOLD II	15 (57.7)	242 (49.6)
GOLD III	8 (30.8)	169 (34.6)
GOLD IV	3 (11.5)	77 (15.8)
MMRC Test (n,%)			0.030
≤ median of 2	15 (57.7)	372 (77.7)
> median of 2	11 (42.3)	107 (22.3)
Inflammation markers
Copeptin, pMol/l	8.24 (10.45)	8.57 (12.53)	0.465
Adrenomedullin, nMol/l	0.60 (0.28)	0.60 (0.3)	0.929
ANP, pMol/l	91.38 (52.43)	83.47 (83.18)	0.408
Procalcitonin, μg/l	0.08 (0.03)	0.08 (0.03)	0.862
SF-36
Physical function	45 (47.5)	50 (45)	0.346
Role physical	50 (100)	50 (100)	0.742
Role emotional	100 (75)	100 (100)	0.518
Social Functioning	75 (65.6)	75 (50)	0.852
Mental Health	67.50 (36.25)	65 (27.50)	0.780
Body Pain	80 (58)	80 (48)	0.720
Vitality	46.88 (32.81)	50 (31.25)	0.403
General Health	37.50 (42.5)	50 (36.69)	0.570
SGRQ
Symptoms score	46.60 (26.87)	49.72 (34.44)	0.356
Activity score	66.19 (31.99)	54.43 (31.81)	0.607
Impact score	29.16 (25.68)	29.39 (26.46)	0.802
Total score	44.15 (31.27)	39.03 (27.54)	0.892

Continuous data are shown as median (interquartile range) and categorical variables as No. (%). Italicized p-values are statistically significant, ie. p < 0.05. BMI body mass index, brd bronchodilator, BODE BMI, airflow obstruction, dyspnea and exercise capacity; 6MWD 6-min walk distance, C3M fragments of collagen type III, C6M fragments of collagen type VI, Pro-C3 pro-forms of collagen type III, Pro-C6 pro-forms of collagen type VI, GOLD Gold Initiative for Chronic Obstructive Lung Disease, MMRC modified Medical Research Council, ANP Atrial Natriuretic Peptide, SF-36 36-item Short-Form Health Survey, SGRQ St. George’s Respiratory Questionnaire
^aGOLD grades are based on FEV1% predicted: 50% ≤ II ≤ 80%; 30% ≤ III ≤ 50%; and IV ≤ 30%

Back to article page

ISSN: 1471-2466

Contact us

Submission enquiries: bmcpulmonarymedicine@biomedcentral.com
General enquiries: ORSupport@springernature.com